222 related articles for article (PubMed ID: 35140677)
1. Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment-A Pilot Study.
Thimm A; Brakemeier S; Kizina K; Munoz Rosales J; Stolte B; Totzeck A; Deuschl C; Kleinschnitz C; Hagenacker T
Front Neurol; 2021; 12():812063. PubMed ID: 35140677
[TBL] [Abstract][Full Text] [Related]
2. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
[TBL] [Abstract][Full Text] [Related]
3. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
[TBL] [Abstract][Full Text] [Related]
4. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
[TBL] [Abstract][Full Text] [Related]
5. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
[TBL] [Abstract][Full Text] [Related]
6. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
[TBL] [Abstract][Full Text] [Related]
7. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study.
Günther R; Wurster CD; Brakemeier S; Osmanovic A; Schreiber-Katz O; Petri S; Uzelac Z; Hiebeler M; Thiele S; Walter MC; Weiler M; Kessler T; Freigang M; Lapp HS; Cordts I; Lingor P; Deschauer M; Hahn A; Martakis K; Steinbach R; Ilse B; Rödiger A; Bellut J; Nentwich J; Zeller D; Muhandes MT; Baum T; Christoph Koch J; Schrank B; Fischer S; Hermann A; Kamm C; Naegel S; Mensch A; Weber M; Neuwirth C; Lehmann HC; Wunderlich G; Stadler C; Tomforde M; George A; Groß M; Pechmann A; Kirschner J; Türk M; Schimmel M; Bernert G; Martin P; Rauscher C; Meyer Zu Hörste G; Baum P; Löscher W; Flotats-Bastardas M; Köhler C; Probst-Schendzielorz K; Goldbach S; Schara-Schmidt U; Müller-Felber W; Lochmüller H; von Velsen O; ; Kleinschnitz C; Ludolph AC; Hagenacker T
Lancet Reg Health Eur; 2024 Apr; 39():100862. PubMed ID: 38361750
[TBL] [Abstract][Full Text] [Related]
10. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
Yao X; Peng J; Luo R; Wang X; Lu X; Wu L; Jin R; Zhong J; Liang J; Hong S; Yang L; Zhang X; Mao S; Hu J; Tao Z; Sun D; Wang H; Zhang L; Xia Y; Chen K; Wang Y
J Neurol; 2024 Jul; ():. PubMed ID: 38954034
[TBL] [Abstract][Full Text] [Related]
14. Effect of nusinersen treatment on quality of life and motor function in adult patients with spinal muscular atrophy.
Şimşek Erdem N; Güneş Gencer GY; Alaamel A; Uysal H
Neuromuscul Disord; 2024 Mar; 36():28-32. PubMed ID: 38310720
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
[TBL] [Abstract][Full Text] [Related]
16. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function.
Dunaway Young S; Montes J; Glanzman AM; Gee R; Day JW; Finkel RS; Darras BT; De Vivo DC; Gambino G; Foster R; Wong J; Garafalo S; Berger Z;
J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568304
[TBL] [Abstract][Full Text] [Related]
18. Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen.
Vidovic M; Freigang M; Aust E; Linse K; Petzold D; Günther R
BMC Neurol; 2023 Jun; 23(1):216. PubMed ID: 37280513
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
